Hamlet Pharma achieves full funding from the European Commission
In a recent evaluation of Hamlet Pharma, the European Commission concluded that Hamlet Pharma’s bladder cancer project has delivered exceptional results with immediate or potential impact. The company was commended by the European Commission for the progress made during the receipt of the EU Horizon 2020 grant in the EIC Accelerator program. The European Commission concluded that the project has fully achieved its objectives and milestones for the period.After this positive report, the Commission will now transfer to Hamlet Pharma a sum of about 300 000 EUR to be used for the bladder cancer